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Abstract
We aggregated genome-wide genotyping data from 32 European-descent GWAS (74,124 T2D 
cases, 824,006 controls) imputed to high-density reference panels of >30,000 sequenced 
haplotypes. Analysis of ˜27M variants (˜21M with minor allele frequency [MAF]<5%), identified 
243 genome-wide significant loci (p<5x10-8; MAF 0.02%-50%; odds ratio [OR] 1.04-8.05), 135 
not previously-implicated in T2D-predisposition. Conditional analyses revealed 160 additional 
distinct association signals (p<10-5) within the identified loci. The combined set of 403 T2D-risk 
signals includes 56 low-frequency (0.5%≤MAF<5%) and 24 rare (MAF<0.5%) index SNPs at 60 
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loci, including 14 with estimated allelic OR>2. Forty-one of the signals displayed effect-size 
heterogeneity between BMI-unadjusted and adjusted analyses. Increased sample size and 
improved imputation led to substantially more precise localisation of causal variants than 
previously attained: at 51 signals, the lead variant after fine-mapping accounted for >80% 
posterior probability of association (PPA) and at 18 of these, PPA exceeded 99%. Integration with 
islet regulatory annotations enriched for T2D association further reduced median credible set size 
(from 42 variants to 32) and extended the number of index variants with PPA>80% to 73. 
Although most signals mapped to regulatory sequence, we identified 18 genes as human validated 
therapeutic targets through coding variants that are causal for disease. Genome wide chip 
heritability accounted for 18% of T2D-risk, and individuals in the 2.5% extremes of a polygenic 
risk score generated from the GWAS data differed >9-fold in risk. Our observations highlight how 
increases in sample size and variant diversity deliver enhanced discovery and single-variant 
resolution of causal T2D-risk alleles, and the consequent impact on mechanistic insights and 
clinical translation.
The analysis of array-based genome-wide association studies (GWAS) has, for the past 
decade, provided the most powerful approach to identify genetic variants contributing to risk 
of complex traits such as type 2 diabetes (T2D). This approach has provided robust detection 
of many thousands of associated regions across many hundreds of traits, including >120 loci 
influencing risk of T2D1–3. Conversion of these genetic discoveries into mechanistic and 
translational insights has often been challenged by the incomplete coverage of the arrays 
used for primary genotyping, imperfect performance of the reference panels available for 
imputation, extensive local linkage disequilibrium (LD), and inadequate sample sizes. This 
has implications for power to detect low-frequency alleles with population-scale impact, to 
deliver clinically-relevant risk prediction, and to define molecular mechanisms involved in 
disease predisposition. In the present study, we address limitations of previous studies by 
combining GWAS data from ˜900,000 European participants with dense, high-quality 
imputation to provide the most comprehensive view to date of the genetic contribution to 
T2D with respect to locus discovery, causal variant resolution, and mechanistic insight.
Results
Study overview
We combined genome-wide association data from 32 studies, including 74,124 T2D cases 
and 824,006 controls of European ancestry (effective sample size 231,436). This represents a 
3.2-fold increase in effective sample size from the previous largest genome-wide study of 
T2D risk in Europeans1. With this sample size, assuming accurate imputation (imputation 
quality score >0.8), we had >80% power to detect T2D association (at α=5x10-8) with 
variants of minor allele frequency (MAF) ≥5% and odds ratio (OR) ≥1.10, or MAF≥0.1% 
and OR≥1.60. After stringent harmonised quality control, 31 of the 32 GWAS were imputed 
using the 64,976 whole-genome sequenced haplotypes of the Haplotype Reference 
Consortium (HRC)4: the exception was the deCODE GWAS, which was imputed using a 
population-specific reference panel based on 30,440 Icelandic whole-genome sequenced 
haplotypes5 (Methods, Supplementary Table 1). We conducted T2D association analyses 
with and without adjustment for body-mass index (BMI).
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Discovery of novel loci for T2D susceptibility
We tested for T2D association with ˜27 million genotyped or imputed variants passing 
quality control filters, 21 million with MAF<5%. Our GWAS meta-analysis identified 
variants at 231 loci at genome-wide significance (p<5x10-8) in the BMI-unadjusted analysis 
and 152 in the smaller (effective sample size 157,401) BMI-adjusted analysis. The BMI-
adjusted signals included 140 overlapping with the BMI-unadjusted analysis and 12 that 
were genome-wide significant only after adjustment. Of these 243 loci, 162 were significant 
at the more stringent threshold of p<5x10-9 recently advocated for whole genome sequence 
data6 (and therefore likely overly conservative for the GWAS setting) (Methods). Of the 243 
significant loci, 135 mapped outside regions previously-implicated in T2D-risk, defined as 
>500kb from reported lead variants (Methods, Figure 1, Supplementary Table 2). The MAF 
of lead variants at the 135 novel loci ranged from 0.02% to 49.7%, including 9 low-
frequency (0.5%≤MAF<5%) and 6 rare (MAF<0.5%) variant signals.
Amongst the samples not included in previous discovery efforts (42,734 cases and 497,261 
controls), we replicated associations (directionally consistent at p<0.05) at 126 of 141 
previously-reported T2D loci, including all 105 regions first discovered in European-only or 
trans-ethnic efforts3,7–9. We also detected significant European signals (p<0.05) for 20 
other loci initially reported in studies focused on non-European subjects10,11. The 15 
signals that did not replicate were all first identified in non-European ancestry samples: at 
six of these, the reported lead variant had MAF<1% in Europeans.
Multiple association signals at T2D susceptibility loci
We used approximate conditional analysis with GCTA12 to delineate distinct association 
signals arising from multiple causal variants in the same locus (Methods). Across the 243 
associated loci, we identified 160 additional signals at “locus-wide” significance (which, as 
in previous T2D analyses, we define using a locus-specific threshold of p<10-5) (Methods), 
110 within previously-reported T2D loci. Of these 160 signals, 92 met a more conservative 
association threshold of p<10-6. Overall, we observed one signal at 151 loci, and two to ten 
signals at the remaining 92 (Supplementary Table 2), for a total of 403 significant T2D-
association signals.
These analyses revealed marked complexity at some of the associated loci. For the first time, 
we observed evidence of multiple association signals at the TCF7L2 locus, the largest-effect 
common variant signal for T2D in Europeans. In all, we detected seven additional distinct 
signals (0.5%<MAF<47.6%, 1.05<OR<1.36), represented by index variants that are, at 
most, in weak LD (r2<0.06) with the previously-reported lead GWAS SNP, rs7903146 (OR 
1.37, MAF 29.3%). Most spectacularly, in the ˜1Mb region that encompasses the 
(previously-annotated) INS-IGF2 and KCNQ1 loci, we found compelling evidence, on 
conditional analyses, for 5 and 10 independent (r2<0.25) non-coding index variants, 
respectively (0.15%<MAF<42.8%,1.03<OR<1.68). The adjacency of these two loci, in a 
region notable for multiple imprinting effects that include many strong biological candidates 
(including INS, IGF2, KCNQ1, and CDKN1C), speaks to a previously-unheralded degree of 
complexity in this T2D-associated telomeric region of chromosome 11.
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The effects of BMI and sex
At most known and novel T2D-loci, there were only minimal differences in statistical 
significance and estimated T2D effect size between BMI-adjusted and unadjusted models 
(Figure 2). However, at the index SNPs for 41 distinct signals (mapping to 21 known and 16 
novel loci), we observed significant heterogeneity in effect sizes between BMI adjusted and 
unadjusted analyses (phet<0.05/403=0.00012 adjusting for 403 variants tested; Methods). 
The heterogeneity in effect sizes followed two distinct patterns. At 26 signals, including 
variants at the FTO, MC4R, TMEM18, SEC16B, and GNPDA2 loci, BMI-adjustment led to 
marked attenuation of signals detected in BMI-unadjusted analysis. These signals display 
strong positive correlation between BMI and T2D effect sizes, and represent T2D-risk 
effects primarily driven by adiposity (Supplementary Table 3, Figure 2). The other 15 were 
more strongly associated in the BMI-adjusted analysis (including two of the 12 signals 
genome-wide significant in BMI-adjusted analyses alone). These reflect a mixture of 
signals, including some with a particularly marked effect on insulin secretion (e.g. TCF7L2, 
ARAP1, JAZF1), and others that likely influence T2D risk through reduced capacity for fat 
storage in peripheral adipose tissue13 (e.g. GRB14, PPARG, HMGA1, ZNF664).
We took advantage of the increased sample size to examine heterogeneity in allelic effects 
between males (41,846 T2D cases; 383,767 controls) and females (30,053 T2D cases; 
434,336 controls). In sex-differentiated meta-analysis14 (Methods), we detected nominal 
evidence of heterogeneity (p<0.05) at 31 of 403 T2D susceptibility signals (7.7%, 
pbinomial=0.013; Supplementary Figures 1, Supplementary Table 3). Variants at 19 signals 
displayed larger effects in females with the most differentiated signals at CMIP (rs2925979, 
female OR=1.09, male OR=1.03, phet=8.3x10-6), KLF14 (rs1562396, female OR=1.09, male 
OR=1.04, phet=0.00048), and MAP3K11 (rs1783541, female OR=1.10, male OR=1.04], 
phet=0.00058). The female-specific effects on T2D risk at KLF1415 are consistent with 
those previously-reported for lipids16 and, given evidence that the risk variant acts as a 
regulator of KLF14 expression in adipose tissue, indicate sexually-dimorphic effects on fat 
deposition. At the other 12 signals, larger effects were seen in males, with the differentiation 
most marked at ANK1 (rs4736819, female OR=1.03, male OR=1.09, phet=0.00021). 
Amongst sex-differentiated signals, only that at CMIP survived Bonferroni correction for 
comparison across 403 T2D loci.
Fine-mapping variants driving T2D association signals
Previous efforts at fine-mapping causal variants within T2D loci have been hampered by 
factors that are both biological (extensive LD) and technical (diverse genotyping scaffolds, 
relatively small reference panels for imputation). We sought to establish the extent to which 
the combination of increased sample size, enlarged reference panel, and harmonised variant 
quality control would enhance fine-mapping resolution. We performed comprehensive fine-
mapping for 380 of the 403 independent T2D association signals, following conditional 
decomposition of loci with multiple signals (Methods). We excluded 23 signals not 
amenable to fine-mapping: (i) 19 where the index variant had MAF<0.25%; (ii) three where 
the index variant was rare and analysed in <50% of the effective sample size; and (iii) the 
one mapping to the major histocompatibility complex because of the extended and complex 
structure of LD across the region, which complicates fine-mapping (Methods). For each of 
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the remaining 380 signals, we constructed credible sets that collectively account for ≥99% of 
the posterior probability of driving the association (PPA), based on the conditional meta-
analysis summary statistics17 (Methods).
As expected, fine-mapping resolution varied markedly across the 380 signals. Credible sets 
included a median of 42 variants (range 1-3,997) distributed across the entire allele-
frequency spectrum (Supplementary Figure 2), and spanned a median of 116kb (range 
1bp-995kb). At 18 signals, the credible set included a single variant; by definition, this 
variant had PPA>99%. For 51 signals, at 44 loci, including 18 novel loci, the most strongly 
associated variant accounted for >80% PPA (Figure 3, Supplementary Table 5).
We explored fine-mapping resolution at the 83 distinct signals where detection in both 
studies allowed us to compare 99% credible sets from the current HRC-based analysis with 
those constructed using the recent meta-analysis of a subset of these T2D GWAS data 
imputed using the 1000G multi-ethnic reference panel1 (26,676 T2D cases; 132,532 controls 
of European ancestry, effective sample size 72,143). Genome-wide, the HRC-based meta-
analysis includes 2.3-fold more variants than the 1000G study. Despite this, the HRC-
imputed analysis resulted in far smaller credible sets: the median number of variants at these 
83 signals decreased from 59 to 10 and the median length of intervals from 60.3kb to 
19.2kb. Overall, at 79 of the 83 signals, HRC-based credible sets were either smaller (72 
signals) than those generated from 1000G or unchanged (seven signals; Figure 4, 
Supplementary Table 6).
This improved resolution likely reflects the combination of: (i) increased effective sample 
size; (ii) improved imputation quality, especially for lower-frequency variants4; and (iii) 
more effective quality control measures harmonised across all contributing studies 
(Methods). To estimate the contribution to fine-mapping resolution attributable to the 
increase in effective sample size (the other two factors are more difficult to tease apart), we 
constructed 99% credible sets based on downscaling the HRC-imputation to a subset of 19 
studies (31,387 cases; 326,742 controls, effective sample size 92,960) that contributed to 
both the 1000G and HRC-based analyses. Amongst 41 single signal loci with p<1x10-5 in 
this downscaled meta-analysis, estimates of credible set size (median 66) and interval 
(median 196kb) indicate that most of the benefits in causal variant resolution achieved in the 
current study derive from increased sample size.
The HRC panel provides excellent coverage of all but very rare SNVs. However, one HRC 
limitation is the absence of indels: these make up 4% of total variants in the phase 3 1000G 
reference panel18. To explore the potential impact on our findings, we considered the 
245,207 indels from the European subset of the 1000G panel that map within 500kb of index 
variants at the 380 fine-mapped signals: these account for 2.8% of variants across the 380Mb 
of sequence. Only 1% of these are in even moderate LD (r2>0.5) with the index variants for 
each distinct signal: this suggests that indel omission is unlikely to have impacted our 
estimates of credible set size.
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The contribution of lower-frequency variants
The limited yield of low-frequency and rare variant signals for T2D in previous GWAS has 
placed an upper bound on their individual and collective contribution to disease risk19. The 
present analysis, with larger sample size and improved imputation, provided far greater 
power in this regard, identifying 56 low-frequency and 24 rare T2D-associated variants 
across 60 loci (Figure 5). At 21 loci, these alleles (15 low frequency, 6 rare) represented the 
strongest regional associations and the remaining 59 were index variants for secondary 
signals. Six of these 80 signals mapped within known T2D loci, five reconfirming earlier 
observations. At the sixth (TMEM18), fine-mapping highlighted the lead regional SNP as 
rs62107261 (MAF=4.6%) rather than the previously-reported common lead variant 
rs2867125 (MAF=17%)2; at this locus, the common and low-frequency variants constitute 
distinct signals, with the former relegated to secondary status in this analysis following 
emergence of the stronger association at rs62107261.
Odds ratios for low-frequency and rare variants ranged from 1.08 to 8.05 (including 14 with 
estimated allelic OR>2), compared to 1.03 to 1.37 for common variants (Figure 5). The 80 
low-frequency and rare risk-variants cumulatively explain only 1.13% of phenotypic 
variance in T2D as compared to the 16.3% attributable to common variant signals. 
Extrapolation beyond these discovered signals to estimate the full contribution of lower-
frequency variants to T2D risk is intrinsically difficult given the combination of effect size 
overestimation in the current study (winner’s curse) and limited power to capture additional 
low-frequency and rare variants of lesser effect. Nonetheless, these data are consistent with 
recently-proposed models for the genetic architecture of T2D derived from modelling 
findings from GWAS and sequencing data19. Put succinctly, although the present study 
leverages increased sample size and improved imputation to expand the number of low-
frequency and rare variants reaching genome-wide (or for secondary signals, locus-wide) 
significance, the effect sizes of the associated low-frequency and rare variants are mostly 
modest, and this limits their collective contribution to heritability. Notwithstanding, the 
identification of low-frequency and rare variants of modest to large effect can provide 
valuable biological inference; here we briefly describe a subset of these signals.
We observed a mix of common and low-frequency variant signals around the NEUROG3 
gene, including T2D risk attributable to the minor alleles at rs41277236 (p.Gly167Arg, 
MAF=4.3%, OR=1.09, p=1.5x10-6) and rs549498088 (non-coding, MAF=0.60%, OR=1.56, 
p=4.7x10-7). NEUROG3 encodes the neurogenin-3 transcription factor known to play a 
central role in the development of pancreatic islets and enteroendocrine cells20. In humans, 
rare homozygous, hypomorphic missense mutations in NEUROG3 (non-overlapping with 
those we detected) are a cause of childhood-onset diabetes associated with severe congenital 
malabsorptive diarrhea21. Age of T2D diagnosis amongst heterozygous and homozygous 
carriers of the low-frequency NEUROG3 T2D-risk alleles we identified was, in UK 
Biobank, similar to that in non-carriers (52.3 vs 52.7 years; p=0.21 for rs41277236; 51.1 vs 
52.7 years; p=0.49 for rs549498088), consistent with a spectrum of functional impact that 
associates these variants with risk of typical T2D. To explore the phenotypic correlates of 
these variants, particularly with respect to the syndromic consequences of severe NEUROG3 
mutations, we conducted “PheWAS” analyses in UK Biobank (Methods). T2D-risk alleles at 
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NEUROG3 were associated with hyperlipidaemia (OR=1.07; p=0.0014) and multiple 
phenotypes recapitulating the gastrointestinal component of the neonatal syndrome 
(including “obstruction of bile duct” [OR=1.29; p=0.023], “gastrointestinal complications” 
[OR=1.79; p=0.024], and “functional digestive disorders” [OR=1.06; p=0.027]).
We identified a rare missense coding variant, p.Cys418Arg in ABCC8 (rs67254669, 
MAF=0.11%, OR=1.89, p=1.1x10-8), which is independent of the existing GWAS lead 
variant in the adjacent KCNJ11 gene (rs5213, MAF=36.2%, OR=1.07, p=3.5x10-27). 
KNCJ11 and ABCC8 encode the two components of the beta-cell KATP channel; loss and 
gain-of-function mutations in both genes have been reported as causal for congenital 
hyperinsulinemia and monogenic diabetes, respectively22–25. The p.Cys418Arg ABCC8 
missense variant has been previously-identified in an individual with recessively-inherited 
congenital hyperinsulinism26. However, the relationship between hyper- and hypo-secretion 
of insulin associated with variation in this locus is dynamic and complex27: some dominant 
ABCC8 mutations have been implicated in the combination of neonatal hyperinsulinism and 
later-onset diabetes.
We detected two previously-unreported rare alleles with large ORs. The first was intronic to 
DENND2C (rs184660829, MAF=0.020%, OR=8.05, p=2.5x10-8). In PheWAS in the UK 
Biobank, the T2D-risk allele was also associated with “lower gastrointestinal congenital 
anomalies” (OR=17.31 p=0.00047), and “disorders of bilirubin excretion” (OR=10.13; 
p=0.022). The second mapped near KIF2B (rs569511541, MAF=0.020%, OR=7.63, 
p=1.5x10-8) and was also associated with “congenital anomalies of endocrine gland” 
(OR=30.75; p=0.00015), “disease of pancreas” (OR=5.93; p=0.0017), and “hypokalemia” 
(OR=6.92; p=0.0046). Both sites are present in the Genome Aggregation Database28 and 
met quality control criteria in our data (average imputation quality >0.7; association signal 
visible in multiple contributing studies), but their precise contribution to T2D-risk requires 
further in vitro and in vivo validation.
Causal coding variants
We next focused attention on the 51 (of 380) signals where our fine-mapping strongly 
implicated (PPA>80%) a single causal variant. Eight of these 51 variants were missense 
coding variants (Supplementary Table 7). Six of the eight fell into established T2D-
associated regions; with the exception of p.Cys130Arg at APOE (MAF=15.4%), all have 
been previously implicated as causal variants for T2D: p.Ser539Trp in PAM (MAF=0.83%); 
p.Thr139Ile in HNF4A (MAF=3.5%); p.Asp1171Asn in RREB1 (MAF=11.3%); 
p.Ala146Val in HNF1A (MAF=2.9%); and p.Pro446Leu in GCKR (MAF=39.3%)3. Coding 
variant associations at PATJ (p.Gly157Val; 9.5% MAF) and CDKN1B (p.Val109Gly; 23.5% 
MAF) are novel and highlight these genes as playing direct roles in T2D-risk. PATJ is highly 
expressed in brain29 and codes for Pals1-Associated Tight Junction component, a protein 
with multiple PDZ domains that mediate protein-protein interactions. In PheWAS, 
associations for this variant indicate a central mechanism of action on T2D: the T2D-risk 
allele is associated with obesity (OR=1.11; p=3.8x10-5; with attenuation of T2D association 
signal in BMI-adjusted analyses, phet=9.3x10-10), hyperlipidemia (OR=1.05; p=0.00048), 
and chronotype (p=7.7x10-12). CDKN1B, encodes a cyclin dependent kinase inhibitor; and 
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in mouse, deletion of this gene ameliorates hyperglycemia by increasing islet mass and 
maintaining compensatory hyperinsulinemia30.
At a further four signals, a single missense variant accounted for the majority (>50%) of the 
PPA. These included two variants previously-reported as causal3: ANKH (p.Arg187Gln, 
MAF=0.6%), and POC5 (p.His36Arg, MAF=39.5%)3 (Supplementary Table 7). The other 
two signals were driven by low-frequency variants: p.Gly167Arg at NEUROG3 (described 
above), and p.Glu4Gln at ZNF771 (MAF=0.6%).
Integration of regulatory annotations to support fine-mapping
Of the 51 variants with PPA>80%, 43 mapped to regulatory sequence: 12 of these were low-
frequency or rare, including variants near ANKH, CCND2, and WDR72. To characterise the 
regulatory impact of these variants, we overlaid them onto chromatin-state maps from T2D-
relevant tissues (islets, liver, adipose, and skeletal muscle31–33) and transcription factor 
binding sites31,32.
Twenty-eight of these variants mapped to islet enhancer or promoter elements; for 14, the 
chromatin states were islet-specific (Supplementary Table 8, Supplementary Figure 3). 
Thirteen of the 14 non-coding variants with PPA≥99% mapped to islet regulatory 
annotations, nine of them islet-specific. These data recapitulate previous findings 
implicating islet regulatory mechanisms driven by rs11257655 at the CDC123-CAMKD1 
locus and rs10830963 near MTNRB133–35, and indicate similar molecular mechanisms 
operate at several other known T2D loci, including IGF2BP2, ANK1, GLIS3, CDKN2B, 
KCNQ1, CCND2, and BCL2A. Novel T2D signals near ABCB10, FAM49A, LRFN2, 
CRHR2, and CASC11 also overlapped with islet-specific enhancer and/or promoter regions. 
High-PPA (i.e. PPA>80%) variants at 13, 10, and 7 signals overlapped with enhancers and/or 
promoters in adipose, skeletal muscle, and liver, respectively. All but four of these were also 
enhancers and/or promoters in islets: one signal (near GLI2) mapped to an adipose-specific 
enhancer, another (near WDR72) to a liver-specific enhancer, and two (near PTGFRN and 
TSC22D2) were located in enhancers in both adipose and skeletal muscle.
We next looked beyond loci where genetic data alone were sufficient to resolve the identity 
of the likely causal variant, and sought to establish whether the integration of genome-wide 
regulatory annotation data could refine mapping resolution where genetic localisation was 
less precise33. For these analyses, we focused on regulatory annotations from human islets 
because: (a) most established T2D-risk variants are considered, given patterns of association 
to continuous metabolic traits, to act through primary effects on beta-cell function3,36,37; 
(b) previous studies have shown that the strongest signal for regulatory enrichment at T2D 
association signals is seen for islet-specific regulatory elements31,34, a view supported by 
the annotation overlaps of the high-PPA (i.e. PPA>80%) variants described above; and (c) 
we had access to particularly extensive, high-resolution epigenomic and chromatin state 
annotation maps for human islets combining available histone modification and transcription 
factor ChIP-seq, ATAC-seq and whole genome bisulphite sequencing33.
Using the hierarchical modelling approach fGWAS38, genome-wide, we observed strong 
and significant (1.9 to 8.2 fold) enrichment of T2D-associated variation with respect to 
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multiple islet enhancer and promoter states, as well as for coding sequence (with 
concomitant depletion of heterochromatin states) (Methods, Supplementary Figure 4). The 
joint annotation model retained strong and weak islet enhancers, strong and weak promoters, 
translational elongation, heterochromatin, (residual) low methylation, and coding sequence 
(Methods, Supplementary Figure 4). We used the parameters from this model as priors to 
redefine 99% credible sets for 380 independent T2D association signals amenable to fine-
mapping (see above). We circumvented the default assumption in fGWAS of a single casual 
variant per locus by conducting these analyses on conditionally-decomposed data (noting 
that this does still allow for the possibility that the association at each conditional signal is 
distributed across multiple variants on a risk haplotype; Methods).
As expected, this integrated fine-mapping analysis boosted the PPA for variants overlapping 
enriched annotations (Figure 5, Figure 6). The median 99% credible set size declined from 
42 to 32, credible intervals from 116kb to 100kb, and the maximum variant PPA per signal 
climbed by a median of 21%. The number of signals at which the lead variant PPA exceeded 
80% increased from 51 to 73, with dramatic increases at some: e.g. at GNG4 the PPA for 
rs291367 climbed from 24.0% to 84.2% (Figure 3).
These annotation-supported analyses highlighted seven additional loci (further to the twelve 
identified on genetic evidence alone) where the majority of the PPA was invested in a coding 
variant (Supplementary Table 7). Three of these had been previously implicated as causal3: 
p.Arg276Trp at SLC30A8 (MAF=31.5%); p.Gly226Ala at HNF1A (MAF=31.1%); and 
p.Thr113Ile at WSCD2 (MAF=26.2%). The other four novel coding variant signals were 
those at QSER1 (p.Arg1101Cys; MAF=4.3%), SCD5 (p.Glu197Gln, MAF=33.8%), IRS2 
(p.Gly1057Asp, MAF=34.0%) and MRPS30 (p.Glu128Gln=MAF 2.8%). In our recent 
study of exome array genotypes, we demonstrated that, for approximately one-third of loci 
harbouring coding variant associations, a causal role could be excluded once information on 
local LD and annotation enrichment was incorporated3. For all 19 coding variants (at 18 
loci) describe in this study, equivalent analyses were consistent with a causal role. These 
analyses therefore provide multiple additional examples of human validated targets at which 
therapeutic modulation has the potential to modify the T2D phenotype.
Next, we concentrated on non-coding variant signals. In the fGWAS analysis, we identified 
15 additional signals (beyond the 43 non-coding signals described above) at which the lead 
variant PPA exceeded 80% (Supplementary Table 8). These signals overlap active regulatory 
sites in islets including strong enhancers (e.g. at TCF7L2, HNF4A, ANKH, RNF6, ZBED3), 
active promoters (EYA2), weak enhancers (ADSCL2, ADCY5, CDKN2B, TBCE), and 
weak promoters (DGKB). For most of these loci, orthogonal data (e.g. associations with 
continuous metabolic traits3,36,37, cis-eQTL data39) are consistent with a role in islet 
function. In contrast, at six signals, including three which are likely, on physiological 
grounds, to be acting, at least partly, through effects on islets, we saw reductions (10% to 
76%) in the lead variant PPA after islet-annotation-informed fGWAS (Supplementary Table 
8). This arose when lead variants from the genetic fine-mapping overlapped annotations 
depleted in the genome-wide model. Examples included variants at the primary CDKAL1 
and secondary KCNQ1 and INS-IGF2 signals, where the index-variant PPA decreased by 
76%, 34%, and 22%, respectively. One explanation is that these reflect T2D-association 
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signals where the phenotypic impact on insulin secretion is mediated through the long-term 
consequences of regulatory influences during islet development that are no longer reflected 
in regulatory annotations seen in mature islets.
At many of these fine-mapped regulatory loci, the integrated data provide novel insights into 
disease mechanism; here we highlight three. In the T2D-association locus near ST6GAL1, 
rs3887925 achieves PPA=98.5% in the genetic data alone (99.3% in fGWAS analysis), and 
overlaps with enhancers active in islet, as well as liver, adipose, and skeletal muscle 
(Supplementary Figure 5). The T2D-risk allele at rs3887925 is associated with a significant 
increase in ST6GAL1 cis-expression specific to islets39, an effect consistent with evidence 
for reduced insulin secretion in risk-allele carriers during provocative testing40. The 
candidate effector transcript, ST6GAL1, encodes β-galactoside α2,6-sialyltransferase-1, a 
key enzyme responsible for the biosynthesis of α2,6-linked sialic acid in N-linked glycans. 
Altered glycation has the potential to impact on multiple processes, and global perturbation 
of ST6GAL1 has broad effects including, in St6gal1 knockout mice, increased body weight 
and visceral fat accumulation41. However, no equivalent association between rs3887925 and 
anthropometric and lipid phenotypes is seen in massive human GWAS studies16,42,43. This 
is consistent with T2D predisposition attributable to the GWAS-detected variant being 
mediated through regulatory mechanisms that are more tissue-specific and focused on the 
modulation of ST6GAL1 expression in islets.
At the ANK1 locus, we observed three distinct (r2<0.08) association signals. The strongest 
causal variant attribution was for the primary signal at rs13262861 (PPA=97.3% on genetic 
data alone; 98.8% with fGWAS). This variant overlaps an islet promoter that lies 3’ to 
ANK1 but 5’ to the transcription factor NKX6.3 (Supplementary Figure 6). The T2D-risk 
allele at the rs13262861 signal shows a directionally-consistent association with both in vivo 
measures of reduced insulin secretion3,37,40, and a cis-eQTL for reduced NKX6-3 
expression in human islets32. Members of the NKX6 transcription factor family (including 
NKX6.3) are implicated in islet development and function44. A recent study describing the 
integration of skeletal muscle regulatory annotations with T2D association data highlighted 
the relationship between variants including rs515071 and rs508419 and the expression and 
splicing of ANK1 in skeletal muscle45; however, all variants influencing ANK1 have 
minimal impact on T2D-risk based on the genetic fine-mapping (PPA<1% in all three 
conditionally-decomposed signals). Collectively, these data indicate that the mechanism of 
T2D predisposition at this locus is more likely to be mediated through reduced islet 
expression of NKX6.3 than altered muscle expression of ANK1.
At the TCF7L2 locus, the patterns of overlap with islet and other annotations across the 
eight distinct T2D-association signals identified on conditional analyses offer a potential 
explanation for the diverse metabolic consequences of TCF7L2 perturbation in humans and 
animal models (Supplementary Table 9)46. The primary signal at rs7903146, long 
established as the largest common variant effect for T2D in Europeans, overlaps an islet 
enhancer (leading to a boost in PPA from 59% to 97% on fGWAS) as well as multiple islet-
relevant transcription factor binding sites, and is located in islet open chromatin47, all 
features consistent with the marked islet phenotype (deficient insulin secretion) evident for 
this variant in non-diabetic individuals8 (Supplementary Figure 7). However, amongst the 
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seven secondary signals, the picture is more mixed. Amongst the four secondary signals 
mapped to credible sets of fewer than 10 variants, only one variant (rs144155527) rises to 
moderate PPA (68%) following islet annotation-enriched fGWAS analysis; many other 
credible set variants map to adipose and liver enhancers, illustrating the potential for their 
T2D-risk effects to be mediated via modulation of TCF7L2 expression in tissues more 
relevant to insulin action.
Heritability estimates and polygenic risk score prediction
Using LD score regression48, and empirical estimates of population- and sample-level T2D 
prevalence48, we estimated chip heritability (on the liability scale) for T2D at 18% 
(Supplementary Figure 8), a figure about half that of median estimates of heritability derived 
from twin and family studies49. Estimates of heritability were slightly greater in females 
(23%) than males (17%), matching observations from a recent study of Europeans 
individuals based on UK Biobank alone50.
Identification of individuals at increased genetic risk for T2D could enhance screening 
strategies and allow targeted prevention. Previous attempts at using genetic data for disease 
prediction have shown limited utility51,52. We revisited this question in the present data set, 
using a BMI-unadjusted meta-analysis of all samples other than UK Biobank to generate 
genome-wide polygenic risk scores (PRS). We then applied these PRS to predict T2D status 
in the 18,197 cases and 423,697 controls from UK Biobank. We tested a series of PRSs, all 
built from 4.6M common variants but using different r2 and p-value thresholds (Methods)53 
for classification performance in UK Biobank. Maximal discrimination (an AUC C-statistic 
of 66%: this AUC is equivalent to that obtained from BMI, age, and sex, in UK Biobank 
individuals) was obtained from a PRS of 136,795 variants (r2>0.6; p<0.076) (Supplementary 
Figure 9). In European subjects from UK Biobank, individuals in the top 2.5% of the PRS 
distribution were at 3.4-fold increased risk (prevalence=11.2%) compared to the median 
(prevalence=3.3%), and 9.4-fold compared to the bottom 2.5% (prevalence=1.2%). The 
modest T2D prevalence rates in UK Biobank reflect the age-distribution of the cohort 
(compared to the age at T2D onset) and preferential ascertainment of healthy individuals. If 
equivalent risk prediction performance applied to the general UK population, this would 
equate to lifetime risks for T2D of ˜51% and ˜5.5% for individuals from those extremes, 
based on current prevalence rates for those over 55 years of age54.
Defining relationships with other traits
To characterise genetic relationships with other biomedical-relevant traits, we used LD score 
regression48 as implemented in LDHub55, testing 182 unique phenotypes, after excluding 
those with low heritability estimates and repeated measures. Eighty-five of those traits 
demonstrated a significant (Bonferroni corrected threshold p<0.00028) genetic correlation 
with T2D. A genetic increase in T2D-risk was, as expected, positively associated with 
multiple cardiometabolic traits including measures of adiposity, hypertriglyceridemia, 
coronary artery disease, and continuous glycemic traits (fasting glucose, insulin; HbA1c). 
(Supplementary Table 10, Supplementary Figure 10) and negatively correlated with HDL-
cholesterol and birth weight.
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These analyses also highlighted a series of more novel examples of significant genetic 
correlation, linking increased T2D-risk to sleeping behaviours (insomnia, excessive daytime 
sleeping), smoking (cigarettes smoked per day, ever versus never smoked), metabolites 
(glycoprotein acetyls, isoleucine, valine), depressive symptoms, urinary albumin-to-
creatinine ratio, and urate. T2D-risk was negatively correlated with anorexia nervosa, 
intelligence, parent’s age at death, lung function measures, education status/duration, age at 
menarche, and age of first birth. We used the BMI-adjusted T2D-association data to 
demonstrate that many of these relationships (including those related to intelligence, 
smoking behaviour, age at menarche, age at first birth and education status) were primarily 
mediated by the shared impact of BMI/obesity on both T2D and the correlated phenotype 
(Supplementary Figure 11).
Discussion
This study demonstrates how substantial increases in sample size combined with more 
accurate and comprehensive imputation expand characterization of the genetic contribution 
to T2D risk. The number of significantly associated genomic regions has doubled to ˜400, 
with a growing harvest of risk-alleles of lower frequency, some with relatively large effects 
(14 with OR>2). At many of these signals, fine-mapping resolution has been substantially 
improved; we mapped 51 of 380 signals to single-variant resolution on genetic evidence 
alone, and demonstrated that the integration of genomic annotations (here focused on those 
from human islets) provides further specification of plausible causal variants. We highlight 
18 genes as human validated targets based on causal coding variant effects and provide novel 
insights into the biological mechanisms operating at several fine-mapped regulatory signals. 
These findings represent mechanistic hypotheses that can now be targeted for large-scale 
empirical validation at both the level of the variants (e.g. through massively parallel reporter 
assays) and the candidate effector genes (through CRISPR screens in appropriate cellular 
models, and manipulation in in vivo models). The present study was limited to individuals of 
European ancestry: integration of these data with large-scale GWAS data from other major 
ancestral groups (as is being pursued by the DIAMANTE consortium) is expected to provide 
an additional boost to locus discovery, and to support further increases in causal variant 




All human research was approved by the relevant institutional review boards, and conducted 
according to the Declaration of Helsinki. All participants provided written informed consent.
Study-level analyses
We considered a total of 74,124 T2D cases and 824,006 controls from 32 GWAS undertaken 
in individuals of European ancestry (Supplementary Table 1), genotyped with a variety of 
genome-wide SNP arrays. Sample and variant quality control was performed within each 
study (Supplementary Table 1). To improve the quality of the genotype scaffold in each 
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study, we developed a harmonised protocol in which variants were subsequently removed if: 
(i) allele frequencies differed from those for European ancestry haplotypes from the HRC 
reference panel4 by more than 20%; AT/GC variants had MAF>40% because of potential 
undetected errors in strand alignment; or (iii) MAF<1% because of difficulties in calling rare 
variants. Each scaffold, with exception of the deCODE GWAS, was then imputed up to the 
HRC reference panel4. The GWAS from deCODE was imputed up to a reference panel 
based on 30,440 Icelandic whole-genome sequences5, and only variants that were present on 
the HRC panel were considered for downstream analyses. Within each study, all variants 
were tested for association with T2D in a regression framework, with and without 
adjustment for BMI, in sex-combined and sex-specific analyses, under an additive model in 
the effect of the minor allele, with additional adjustment for study-specific covariates 
(Supplementary Table 1). To account for population structure and relatedness, association 
analyses were either adjusted for principal components (after excluding related individuals) 
or implemented in a mixed model with random effects for kinship from a genetic 
relationship matrix. For studies analysed using linear mixed models, implemented in 
EMMAX56 or BOLT-LMM57 (Supplementary Table 1), allelic effects and standard errors 
were converted to the log-odds scale to correct for case-control imbalance58. For each 
analysis, in each study, variants were removed from a study if: (i) minor allele count <5 (in 
cases and controls combined); (ii) imputation quality r2-hat<0.3 (miniMAC) or proper-
info<0.4 (IMPUTE4); or (iii) standard error of the allelic log-OR>10. Association summary 
statistics for each analysis within each study were then corrected for residual structure by 
means of genomic control inflation factor59, calculated after excluding variants mapping to 
established T2D susceptibility loci (Supplementary Table 1).
Sex-combined meta-analysis
We aggregated association summary statistics from sex-combined analyses for each variant 
across studies, with and without adjustment for BMI, using fixed-effects meta-analysis with 
inverse-variance weighting of log-ORs, implemented in METAL60. The BMI unadjusted 
meta-analysis was subsequently corrected for residual inflation (to account for structure 
between studies) by means of genomic control (λ=1.013)59, calculated after excluding 
variants mapping to established T2D susceptibility loci. No adjustment was required for the 
BMI adjusted meta-analysis (λ=0.992). From the meta-analysis, variants were extracted that 
passed quality control in at least two studies. Heterogeneity in allelic effect sizes between 
studies contributing to the meta-analysis was assessed by Cochran’s Q statistic61. We 
defined novel loci as mapping >500kb and conditionally independent from a previously 
reported lead GWAS SNP.
For the present study, we maintained the conventional genome-wide significance threshold 
of 5x10-8, for compatibility with previous reports. We recognise that more comprehensive 
capture of lower-frequency variants in particular increases the effective number of tests, with 
some consequent increase in the false positive rate for signals just below this threshold. 162 
of the 243 primary signals are significant at a more stringent threshold (5x10-9) recently 
advocated for whole genome sequence data6, and the major conclusions of the manuscript 
are unchanged if we select this more stringent (and given that our data lack the full coverage 
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of WGS data, over-conservative) threshold. We make all summary level data results 
available so that readers can interpret the results themselves.
Sex-differentiated meta-analysis
The meta-analyses described above were repeated for males and females separately, with 
correction for population structure by genomic control as necessary: (i) male-specific BMI 
unadjusted λ=1.029; (ii) male-specific BMI adjusted λ=1.001; (iii) female-specific BMI 
unadjusted λ=0.955; and (iv) female-specific BMI adjusted λ=0.932. The male-specific 
meta-analysis consisted of up to 41,846 cases and 383,767 controls, whilst the female-
specific meta-analysis consisted of up to 30,053 cases and 434,336 controls. The sex-
specific meta-analyses were then combined to conduct a sex-differentiated test of association 
and a test of heterogeneity in allelic effects between males and females14.
Assessment of effect of BMI adjustment
We compared the genetic effect sizes (beta coefficients) estimated from models with and 
without BMI adjustments using a matched meta-analysis conducted on the same subset of 28 
studies:
βnoBMI − βBMI / SE βnoBMI 2 + SE βBMI 2 − 2ρ × SE βnoBMI × SE βBMI ,
where βBMI and βnoBMI are the estimated genetic effects from models with and without BMI 
adjustment, SE(β) is the estimated standard error of the estimates, and ρ = 0.89, is the 
estimated correlation between βBMI and βnoBMI across all variants1.
Detection of distinct association signals
We used GCTA12 to perform approximate conditional analyses to detect distinct association 
signals at each of the genome-wide significant risk loci for T2D (newly identified or 
confirmed, except at the major histocompatibility complex (MHC) region). GCTA performs 
conditional analysis using association summary statistics from GWAS meta-analysis and 
estimated LD from a sufficiently large reference study used in the meta-analysis. We used a 
reference sample of 6,000 (nearly) unrelated (pairwise relatedness <0.025) individuals of 
white British origin, randomly selected from the UK Biobank, to model patterns of LD 
between variants. The reference panel of genotypes consisted of the same 39 million variants 
from the HRC reference panel assessed in our GWAS, but with an additional quality control 
step to exclude SNPs with low imputation quality (proper-info<0.4) or deviation from 
Hardy-Weinberg equilibrium (p<1x10-6). For each locus, we first searched ±500kb 
surrounding the lead SNP (using summary statistics from BMI unadjusted or adjusted 
analysis, as appropriate) to ensure potential long-range genetic influences were assessed. 
Within a region, conditionally independent variants that reached locus-wide significance 
(p<10-5) were considered as index SNPs for distinct association signals. If the minimum 
distance between any distinct signals from two separate loci was less than 500kb, we 
performed additional conditional analysis taking both regions (encompassing ±500kb from 
both ends) and reassessed the independence of each signal.
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Fine-mapping of distinct association signals with T2D susceptibility
We considered 380 of the 403 identified distinct signals, excluding 23 that were not 
amenable to fine-mapping: (i) 19 signals with MAF<0.25%; (ii) three signals where the 
index variant was rare and analysed in <50% of the total effective sample size, defined as Ne 
= 4 × Ncases × Ncontrols/(Ncases + Ncontrols); and (iii) the one signal in the major 
histocompatibility complex because of the extended and complex structure of LD across the 
region, which complicates fine-mapping.
For each of the remaining distinct signals, we first defined a genomic region 500kb on either 
side of the index variant, considering only variants with MAF>0.25% that were reported in 
at least 50% of the total effective sample size, thus removing those that were not well 
imputed in the majority of samples. We then adopted two approaches to compute 99% 
credible sets with 99% posterior probability of containing the causal variant: (i) using a 
(functionally unweighted) Bayesian approach, with the strength of evidence for association 
measured using the Bayes’ factor in favour of association for each variant17,62; and (ii) 
using (functionally weighted) fGWAS38 that reweights the association measures by using 
information from functional genomics data.
(i) Genetic credible sets—For each distinct association signal, we first calculated an 
approximate Bayes factor62 in favour of association on the basis of allelic effect sizes and 
standard errors from the meta-analysis (using BMI-unadjusted or adjusted meta-analysis, as 
appropriate). For loci with a single association signal, effect sizes and standard errors from 
unconditional meta-analysis were used. For loci with multiple distinct association signals, 
these parameters were derived from the approximate conditional analysis adjusting for all 
other index variants in the region. Specifically, for the jth variant,
Λ j =
V j




2V j V j + ω
,
where βj and Vj denote the estimated allelic effect (log-OR) and corresponding variance 
from the meta-analysis. The parameter ω denotes the prior variance in allelic effects, taken 
here to be 0.0462.






The 99% credible set17 for each locus was then constructed by: (i) ordering all variants in 
descending order of their PPA; and (ii) including ordered variants until the cumulative PPA 
reached 0.99. The number of variants and length of the genomic region covered by each 
99% credible set was then calculated.
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(ii) Functionally weighted credible sets—We first tested each of the 15 chromatin 
states in human islets and coding DNA sequence separately for enrichment using genome-
wide data with the program fGWAS38. Details on generation of the 15 chromatin states have 
been described elsewhere33. The annotation with the most significant enrichment was 
retained and tested jointly with each remaining annotation. If the most significant two 
annotation model improved the model likelihood then the two annotations in the model were 
retained and the process continued until the model likelihood did not exceed the previous 
iteration. The resulting “full” model was iteratively pruned by dropping each annotation and 
assessing the cross-validated likelihood of the reduced model (i.e. an annotation was 
removed from the “full” model if dropping it increased the cross-validated likelihood). This 
process resulted in the “best joint model”.
By default, fGWAS partitions the genome into “blocks” of 5,000 SNPs and assumes no more 
than one causal variant per block. However, for direct comparison with the “genetic” 
credible sets and to account for multiple distinct association signals within a locus, we used 
a modified approach. For T2D associated regions with no evidence of more than one distinct 
signal, we delineated 1Mb windows comprising all SNPs within 500 kb of the index variant 
and partitioned the intervening regions into ˜1Mb windows. These windows were manually 
input into fGWAS using the --bed command and a separate fGWAS analysis was performed 
using only the set of annotations remaining in the “best joint model”. The genome-wide 
enrichments were used as priors in a Bayesian fine-mapping analysis implemented in 
fGWAS to calculate posterior probabilities for each SNP in the designated windows. For the 
remaining regions with evidence of two or more distinct association signals, we used the 
results from the approximate conditional analyses described above and similarly performed 
a manually partitioned fGWAS analysis. We then constructed 99% credible sets as described 
above.
PheWAS analyses
We performed phenome-wide association studies (PheWAS) using genotype and phenotype 
data from electronic health records (EHRs) from the UK Biobank. Hierarchical phenotype 
codes from EHRs were curated by grouping International Classification of Disease, Ninth 
Revision (ICD-9) clinical/billing codes as previously described63. Only phenotype codes 
with 20 or more cases and with minor allele count of 5 or greater in cases and controls were 
considered eligible for analysis. Logistic regression analyses were performed in individuals 
of European ancestry for relevant phenotype-genotype combination adjusting for six genetic 
ancestry principal components, array, and sex.
Estimation of genetic variance explained
We used Linkage Disequilibrium Score Regression (LDSR)48 to estimate the proportion of 
variance explained by common genetic variants for T2D on the liability scale. As advised by 
the developers, these estimates were based on summary statistics (without any genomic 
control correction) of variants restricted to the subset of HapMap64 variants after excluding 
the MHC region. Estimations were done for both sex-combined and sex-specific (BMI-
unadjusted) analyses, assuming population prevalence of 10%.
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Estimating phenotypic variance explained by SNPs
We used UK Biobank samples (19,119 T2D cases and 423,698 controls) to calculate 
variance explained by genome-wide significant variants. We ran a model regressing T2D 
status on all independently associated rare and low-frequency variants, assuming an additive 
model (and adjusting for sex, age, array, and 6 principal components). A separate model was 
run to determine the variance captured by the independently associated common variants.
Polygenic risk score analyses
Polygenic risk score (PRSs) were created in UK Biobank samples using raw genotype data 
using the software PRsice53 using the GWAS summary statistics from the sex-combined 
BMI-unadjusted T2D meta-analysis excluding UK Biobank samples. PRSs were created 
using p-value thresholds ranging from 5x10-8 to 0.5 using LD pruning parameters of r2 0.2 
to 0.8 over 250 kb windows.
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Figure 1. Manhattan plots of the sex-combined BMI-unadjusted and adjusted meta-analysis for 
T2D.
a, Manhattan plot (top panel) of genome-wide association results for T2D without BMI 
adjustment from meta-analysis of up to 71,124 cases and 824,006 controls. The association 
p-value (on -log10 scale) for each SNP (y-axis) is plotted against the genomic position 
(NCBI Build 37; x-axis). Association signals that reached genome-wide significance 
(p<5x10-8) are shown in purple if novel. b, Manhattan plot (bottom panel) of genome-wide 
association results for T2D with BMI adjustment from meta-analysis of up to 50,409 cases 
and 523,897 controls. Novel association signals that reached genome-wide significance 
(p<5x10-8) only in the BMI-unadjusted analysis are shown in orange.
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Figure 2. Comparison of estimated T2D effect size between BMI-adjusted and unadjusted 
models.
Z-score for each of the 403 distinct signals from BMI-unadjusted analysis (50,791 cases and 
526,121 controls; x-axis) is plotted against the z-score from the BMI-adjusted analysis 
(50,402 cases and 523,888 controls; y-axis). Variants that display higher T2D effect size in 
BMI-adjusted analysis are shown in red and variants with higher T2D effects in BMI-
unadjusted analysis are shown in blue. Diameter of the circle is proportional to -log10 
heterogeneity p-value.
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Figure 3. Summary of fine-mapped associations.
a, Distinct association signals. A single signal at 151 loci, and 2-10 signals at 92. b, Number 
of variants in genetic and functional 99% credible sets. Eighteen and 23 signals were 
mapped to a single variant in genetic and functional credible sets, respectively. c, 
Distribution of the posterior probability of association of the variants in credible sets.
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Figure 4. Comparison of fine-mapping resolution at 83 distinct signals.
The number of variants included in the 99% credible set for each of the 83 distinct signals 
constructed using meta-analysis of GWAS data imputed using the 1000G multi-ethnic 
reference panel (26,676 T2D cases and 132,532 controls) (x-axis; logarithmic scale) is 
plotted against those (y-axis; logarithmic scale) derived using HRC-based imputation 
(74,124 T2D cases and 824,006 controls). Inset presents the same plot but with linear scales.
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Figure 5. The relationship between effect size and minor allele frequency.
Conditional and joint analysis effect size (y-axis) and minor allele frequency (x-axis) for 403 
conditionally independent SNPs. Previously-reported T2D associated variants are shown in 
green and novel variants are shown in purple. Stars and circles represent the “strongest 
regional lead at a locus” and “lead variants for secondary signals”, respectively.
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Figure 6. Comparison of posterior probability of association for each variant with and without 
incorporation enrichment information.
Posterior probability of association from genetic credible sets (y-axis) and fGWAS analysis 
(x-axis) for each variant included in the 99% credible sets.
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